title: An important new adaption of a specific drug?
authors.forename: Massimo
authors.initials: M
authors.lastname: Manno
authors.forename: Francesco
authors.initials: F
authors.lastname: Tomei
authors.forename: Emanuela
authors.initials: E
authors.lastname: Marchesan
authors.forename: Valter
authors.initials: V
authors.lastname: Adamo
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006062:Gonadotropins / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy* / Q000209:etiology*; D010911:Pituitary Neoplasms / Q000150:complications* / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D006062:Gonadotropins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077465:Cabergoline